Current and historical daily PE Ratio for Braxia Scientific Corp (
) from 2020 to Jun 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Braxia Scientific stock (XCNQ:BRAX) PE ratio as of Jun 17 2024 is 0.
More Details
Braxia Scientific Corp (XCNQ:BRAX) PE Ratio (TTM) Chart
Braxia Scientific Corp (XCNQ:BRAX) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 940
- 1
- 2
- 3
- 4
- 5
- 6
- 11
Braxia Scientific PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-29 | At Loss |
2024-05-31 | At Loss | 2024-03-28 | At Loss |
2024-05-30 | At Loss | 2024-03-27 | At Loss |
2024-05-29 | At Loss | 2024-03-26 | At Loss |
2024-05-28 | At Loss | 2024-03-25 | At Loss |
2024-05-27 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-17 | At Loss | 2024-03-15 | At Loss |
2024-05-16 | At Loss | 2024-03-14 | At Loss |
2024-05-15 | At Loss | 2024-03-13 | At Loss |
2024-05-14 | At Loss | 2024-03-12 | At Loss |
2024-05-13 | At Loss | 2024-03-11 | At Loss |
2024-05-10 | At Loss | 2024-03-08 | At Loss |
2024-05-09 | At Loss | 2024-03-07 | At Loss |
2024-05-08 | At Loss | 2024-03-06 | At Loss |
2024-05-07 | At Loss | 2024-03-05 | At Loss |
2024-05-06 | At Loss | 2024-03-04 | At Loss |
2024-05-03 | At Loss | 2024-03-01 | At Loss |
2024-05-02 | At Loss | 2024-02-29 | At Loss |
2024-05-01 | At Loss | 2024-02-28 | At Loss |
2024-04-30 | At Loss | 2024-02-27 | At Loss |
2024-04-29 | At Loss | 2024-02-26 | At Loss |
2024-04-26 | At Loss | 2024-02-23 | At Loss |
2024-04-25 | At Loss | 2024-02-22 | At Loss |
2024-04-24 | At Loss | 2024-02-21 | At Loss |
2024-04-23 | At Loss | 2024-02-20 | At Loss |
2024-04-22 | At Loss | 2024-02-19 | At Loss |
2024-04-19 | At Loss | 2024-02-16 | At Loss |
2024-04-18 | At Loss | 2024-02-15 | At Loss |
2024-04-17 | At Loss | 2024-02-14 | At Loss |
2024-04-16 | At Loss | 2024-02-13 | At Loss |
2024-04-15 | At Loss | 2024-02-12 | At Loss |
Braxia Scientific Corp (XCNQ:BRAX) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Braxia Scientific Corp Braxia Scientific Corp logo](https://static.gurufocus.com/logos/0C0000BS9Y.png?14)
Braxia Scientific Corp
NAICS : 325412
SIC : 3741
ISIN : CA1057361026
Share Class Description:
XCNQ:BRAX: Ordinary SharesCompare
Compare
Traded in other countries / regions
BRAX.CanadaBRAXF.USA4960.Germany IPO Date
2020-02-27Description
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.